Cipla Limited reported a 10% rise on Wednesday in its profit for this June quarter to INR 451 crore due to better sales in South Africa and India. While Cipla had registered a net profit of INR 408.8 crore for the same quarter a year ago.<\/p>\n
Currently, the company\u2019s YOY is INR 4,109.10 crore which is 12 percent higher in this quarter under review. The EBITDA margin grew 330 basis points to the 18.4 in the quarter 1 for FY19. On a quarter-on-quarter, the revenue of Cipla rose 14 percent.<\/p>\n
In India, Cipla reported a strong performance in Urology, Cardiology, Respiratory & CNS segments. During the Q1, the company launched special cancer biologic drugs Trastuzumab, rituximab and Bevacizumab in partnership with Roche. Cipla partnered with Eli Lilly to distribute and market the insulin glargine injection in India.<\/p>\n
In the private market, Cipla limited rose to 15% above the industrial growth of 7%. Recently, it signed deals with Columbia, New Zealand, Australia and Malaysia to market & distribute Trastuzumab – a breast cancer drug.<\/p>\n
On 8 August 2018, 15:39 the stock was quoting at INR 632.55 up INR 3.10 or up 0.49%.<\/p>\n","protected":false},"excerpt":{"rendered":"
Cipla Limited reported a 10% rise on Wednesday in its profit for this June quarter to INR 451 crore due…<\/p>\n","protected":false},"author":1,"featured_media":945,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[12,10,19,8],"tags":[],"yoast_head":"\n